# Phase 4 Acute Coronary Syndrome trials recruiting: 32 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 4 for Acute Coronary Syndrome that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 4 Acute Coronary Syndrome trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-4/acute-coronary-syndrome

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939516 | Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome | Medisch Spectrum Twente | Phase 4 | Not yet recruiting | Acute Coronary Syndromes (ACS), Unstable Angina Pectoris, Myocardial Infarction (MI), STEMI, NSTEMI | 3,120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939516) |
| September 17, 2026 | NCT07824323 | Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome | Taipei Medical University Hospital | Phase 4 | Recruiting | Acute Coronary Syndromes, Dyslipidemia | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824323) |
| September 2, 2026 | NCT07799779 | Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome | Seoul National University Bundang Hospital | Phase 4 | Not yet recruiting | Acute Coronary Syndromes (ACS) | 294 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07799779) |
| July 30, 2026 | NCT07736196 | Aspirin-Free Strategy After 3-6 Month Dual Antiplatelet Therapy in Acute Coronary Syndrome | Assiut University | Phase 4 | Not yet recruiting | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Dual Anti-platelet Therapy | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736196) |
| July 6, 2026 | NCT07684742 | Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome | Gyeongsang National University Hospital | Phase 4 | Recruiting | Acute Coronary Syndromes, STEMI, NSTEMI, Unstable Angina | 2,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684742) |
| July 6, 2026 | NCT07684469 | Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary... | Novartis Pharmaceuticals | Phase 4 | Not yet recruiting | Acute Coronary Syndrome | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684469) |
| July 6, 2026 | NCT07683923 | Spontaneous Coronary Artery Dissection - AntipLatelet Therapy Intensity in Guided coNservative Management (SCAD-ALIGN) Trial | Universitätsklinikum Hamburg-Eppendorf | Phase 4 | Not yet recruiting | SCAD, ACS (Acute Coronary Syndrome) | 3,518 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683923) |
| May 29, 2026 | NCT07612774 | CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS | West China Hospital | Phase 4 | Recruiting | Coronary, Coronary Artery Disease | 232 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612774) |
| April 6, 2026 | NCT07511257 | Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia | Instituto Nacional de Cardiologia Ignacio Chavez | Phase 4 | Recruiting | Coronary Artery Ectasia, Acute Coronary Syndromes (ACS), STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST... | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511257) |
| April 2, 2026 | NCT07508254 | Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome | Punjab Institute of Cardology | Phase 4 | Not yet recruiting | Acute Coronary Syndromes (ACS), Hypercholesterolemia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07508254) |
| April 2, 2026 | NCT07507500 | Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Phase 4 | Recruiting | Myocardial Infarction (MI) | 8,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07507500) |
| March 17, 2026 | NCT07476859 | Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome | Fundación para la Investigación del Hospital Clínico de Valencia | Phase 4 | Recruiting | Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More) | 538 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476859) |
| February 3, 2026 | NCT07383155 | Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes | Shenyang Northern Hospital | Phase 4 | Not yet recruiting | Percutaneous Coronary Intervention, High Bleeding Risk, Acute Coronary Syndromes, Anticoagulant Therapy | 5,270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07383155) |
| January 20, 2026 | NCT07351643 | CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome | Shenyang Northern Hospital | Phase 4 | Recruiting | ACS (Acute Coronary Syndrome), SGLT2 Inhibitors | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07351643) |
| October 2, 2025 | NCT07203846 | Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor | Collegium Medicum w Bydgoszczy | Phase 4 | Not yet recruiting | ACS - Acute Coronary Syndrome, Ticagrelor, Microbiota, Platelet Aggregation, Myocardial Infarction (MI), Blood... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07203846) |
| March 4, 2025 | NCT06855537 | Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques | Beijing Anzhen Hospital | Phase 4 | Recruiting | Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques, Thin-cap fIbroatheroma, Acute Coronary Syndromes (ACS) | 2,190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06855537) |
| January 9, 2025 | NCT06765265 | Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome | King Edward Medical University | Phase 4 | Recruiting | Acute Coronary Syndromes | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06765265) |
| January 8, 2025 | NCT06763744 | Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR | Samsung Medical Center | Phase 4 | Not yet recruiting | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06763744) |
| January 6, 2025 | NCT06759272 | Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome), SCAD | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06759272) |
| August 7, 2024 | NCT06543082 | MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study | CHA University | Phase 4 | Recruiting | Acute Coronary Syndrome | 490 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06543082) |
| July 19, 2024 | NCT06509074 | Beta-Blockers in Takotsubo Syndrome Study | Spanish Society of Cardiology | Phase 4 | Not yet recruiting | Takotsubo Cardiomyopathy, Beta-blockers, Echocardiography, Left Ventricular Function | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06509074) |
| May 20, 2024 | NCT06421363 | Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart Disease | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Ischemic Heart Disease, Acute Coronary Syndrome | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06421363) |
| February 28, 2024 | NCT06283888 | CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention | Zunyi Medical College | Phase 4 | Recruiting | ACS - Acute Coronary Syndrome, CYP2C19 Polymorphism | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06283888) |
| October 24, 2023 | NCT06096909 | Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population | China National Center for Cardiovascular Diseases | Phase 4 | Recruiting | Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome, Lipid Lowering, Vascular Inflammation | 3,684 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06096909) |
| December 6, 2022 | NCT05638867 | NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | China National Center for Cardiovascular Diseases | Phase 4 | Recruiting | Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome | 3,944 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05638867) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Shenyang Northern Hospital | 2 |
| China National Center for Cardiovascular Diseases | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 1 |
| Samsung Medical Center | 1 |
| Collegium Medicum w Bydgoszczy | 1 |
| Fu Wai Hospital, Beijing, China | 1 |
| CHA University | 1 |
| Seoul National University Bundang Hospital | 1 |
| Medisch Spectrum Twente | 1 |
| Punjab Institute of Cardology | 1 |
| Beijing Anzhen Hospital | 1 |
| CoreAalst BV | 1 |
| Assiut University | 1 |
| Medical University of Gdansk | 1 |
| St. Antonius Hospital | 1 |
| Instituto Nacional de Cardiologia Ignacio Chavez | 1 |
| Universitätsklinikum Hamburg-Eppendorf | 1 |
| Gyeongsang National University Hospital | 1 |
| King Edward Medical University | 1 |
| West China Hospital | 1 |
| Spanish Society of Cardiology | 1 |
| Taipei Medical University Hospital | 1 |
| Zunyi Medical College | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 10 |
| Spain | 5 |
| South Korea | 5 |
| Poland | 4 |
| Netherlands | 4 |
| Pakistan | 2 |
| Belgium | 2 |
| Germany | 2 |
| Ireland | 1 |
| Latvia | 1 |
| Norway | 1 |
| France | 1 |
| Italy | 1 |
| Egypt | 1 |
| Mexico | 1 |
| Malaysia | 1 |
| Canada | 1 |
| Sweden | 1 |
| United Kingdom | 1 |
| Taiwan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Spices wholesalers in the United States](https://specstream.ai/data/businesses/spices-wholesalers/united-states)
- [Speech training companies in the United States](https://specstream.ai/data/businesses/speech-training-companies/united-states)
- [Speech therapy clinics in the United States](https://specstream.ai/data/businesses/speech-therapy-clinics/united-states)
- [Specialty schools in the United States](https://specstream.ai/data/businesses/specialty-schools/united-states)
- [Specialty hospitals in the United States](https://specstream.ai/data/businesses/specialty-hospitals/united-states)
- [Specialized medical facilities in the United States](https://specstream.ai/data/businesses/specialized-medical-facilities/united-states)
